AlphaCentric Advisors LLC cut its position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE – Free Report) by 13.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 268,485 shares of the company’s stock after selling 42,015 shares during the quarter. AlphaCentric Advisors LLC owned approximately 1.82% of VYNE Therapeutics worth $505,000 as of its most recent SEC filing.
Separately, Lynx1 Capital Management LP purchased a new position in VYNE Therapeutics during the second quarter worth about $32,000. Institutional investors and hedge funds own 83.78% of the company’s stock.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and set a $5.75 price target on shares of VYNE Therapeutics in a report on Thursday, September 12th.
VYNE Therapeutics Stock Performance
VYNE Therapeutics stock opened at $2.99 on Tuesday. VYNE Therapeutics Inc. has a fifty-two week low of $1.57 and a fifty-two week high of $4.48. The stock has a market cap of $44.10 million, a PE ratio of -1.16 and a beta of 1.32. The firm’s 50-day simple moving average is $2.06 and its 200 day simple moving average is $2.15.
VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The company had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.11 million. VYNE Therapeutics had a negative return on equity of 43.11% and a negative net margin of 5,849.18%. As a group, analysts predict that VYNE Therapeutics Inc. will post -0.86 EPS for the current fiscal year.
About VYNE Therapeutics
VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.
Further Reading
- Five stocks we like better than VYNE Therapeutics
- How to Calculate Inflation Rate
- Mobileye’s Recovery Steadily Gains Traction with Novel AI
- Stock Splits, Do They Really Impact Investors?
- Options Traders Bet Big on These 3 Tech Stocks
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Rise of AI Agents vs. RPA Bots: 3 Stocks to Watch Now
Want to see what other hedge funds are holding VYNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VYNE Therapeutics Inc. (NASDAQ:VYNE – Free Report).
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
